<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866449</url>
  </required_header>
  <id_info>
    <org_study_id>C-GBM (XRP6258)</org_study_id>
    <nct_id>NCT01866449</nct_id>
  </id_info>
  <brief_title>Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme</brief_title>
  <official_title>Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is an open-label, single-arm, Phase- II trial to assess the efficacy of&#xD;
      cabazitaxel in GBM WHO grade IV patients with a progression during or within 6 months after&#xD;
      last temozolomide treatment (Figure 1).&#xD;
&#xD;
      Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks with standard&#xD;
      concomitant medication (as outlined below):&#xD;
&#xD;
        -  On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25mg/m²,&#xD;
           administered by i.v. route in 1 hour.&#xD;
&#xD;
        -  Cycle length for cabazitaxel is 3 weeks (21 days).&#xD;
&#xD;
        -  New cycles of therapy may not begin until Absolute Neutrophil Count (ANC) ≥1500/mm3,&#xD;
           platelet count ≥75 000/mm3, and non-hematological toxicities (except alopecia) have&#xD;
           recovered to baseline.&#xD;
&#xD;
        -  A maximum of 2 weeks (14 days) delay is allowed between 2 treatment cycles.&#xD;
&#xD;
        -  Patients should come off treatment if treatment delay is more than 2 weeks.&#xD;
&#xD;
      At least 30 minutes prior to each administration of cabazitaxel, patients will receive i.v.&#xD;
      premedication including:&#xD;
&#xD;
        -  An antihistamine (dexchlorpheniramine 5mg, diphenhydramine 25mg, or equivalent). In case&#xD;
           of i.v. antihistamine other than promethazine is not being available, local practice&#xD;
           should be followed.&#xD;
&#xD;
        -  Corticosteroid (dexamethasone 8mg or equivalent)&#xD;
&#xD;
        -  H2 antagonist (ranitidine or equivalent).&#xD;
&#xD;
        -  Antiemetic prophylaxis is recommended and can be given orally or intravenously if&#xD;
           necessary.&#xD;
&#xD;
        -  Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) should be given&#xD;
           on day 4 of each treatment cycle as per ASCO and ESMO guidelines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 25, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response including SD, PR or CR determined by MRI (modified RANO criteria)</measure>
    <time_frame>1 year</time_frame>
    <description>• Response after 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>3 years</time_frame>
    <description>Rates of deaths within 12 weeks&#xD;
Hematological and non hematological toxicity grade ≥ 2 according to CTCAE V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction)</measure>
    <time_frame>3 years</time_frame>
    <description>Pharmacokinetics of cabazitaxel in patients with and without concomitant anticonvulsive medication with respect to induction of CYP3A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and neurocognitive functioning</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of quality of life, determined by assessment with EORTC QLQ questionnaires (C30 and BN20), and neurocognitive functioning, determined by repeated standardized measurements using MMSE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Glioblastoma Multiforme (GBM) WHO Grade IV</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both female and male patients meeting the mentioned inclusion and exclusion criteria&#xD;
             will be included in this clinical trial. Patients must meet ALL of the following&#xD;
             inclusion criteria to be eligible for enrollment into the study:&#xD;
&#xD;
               -  Patients with diagnosis glioblastoma multiforme (GBM) WHO grade IV&#xD;
                  (histologically confirmed by a pathologist)&#xD;
&#xD;
               -  Progression during or within 6 months after last temozolomide treatment&#xD;
&#xD;
               -  Time since last temozolomide &gt; 21 days&#xD;
&#xD;
               -  Prior external beam radiotherapy (54 to 62 Gy), no option for subsequent&#xD;
                  radiotherapy&#xD;
&#xD;
               -  No clinical and radiological signs of intracerebral inflammation (in pre-study&#xD;
                  MRI not older than 4 weeks)&#xD;
&#xD;
               -  Patients &gt; 18 years of age.&#xD;
&#xD;
               -  ECOG performance status of ≤ 2 (stable over 4 weeks prior to study entrance)&#xD;
&#xD;
               -  Female patients of childbearing potential with a negative pregnancy test within 7&#xD;
                  days of initiation of study treatment. Postmenopausal women must be amenorrheic&#xD;
                  for at least 12 months to be considered of non-childbearing potential.&#xD;
&#xD;
               -  Male and female patients of reproductive potential who agree to employ an&#xD;
                  effective method of birth control throughout the study and for up to 6 months&#xD;
                  following discontinuation of study drug.&#xD;
&#xD;
               -  Signed informed consent prior to initiation of any study procedure (Must&#xD;
                  understand, voluntarily sign the informed consent form and be able to adhere to&#xD;
                  the study visit schedule and other protocol requirements.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of ANY of the following criteria will exclude a patient from study&#xD;
             enrollment:&#xD;
&#xD;
               -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
               -  History of severe hypersensitivity reaction (≥grade 3) to any component of the&#xD;
                  investigational drugs or excipients (allergy to or other intolerability of&#xD;
                  gadolinium, docetaxel, cabazitaxel or polysorbate 80 containing drugs)&#xD;
&#xD;
               -  Unable to undergo Gd-MRI&#xD;
&#xD;
               -  Time since external beam radiotherapy &lt;12 weeks&#xD;
&#xD;
               -  Patients who have been treated with any investigational agent(s) within 28 days&#xD;
                  of the first day of administration of study drug.&#xD;
&#xD;
               -  Current active second malignancy other than non-melanoma skin cancers and&#xD;
                  post-treatment of localized prostate cancer. Patients are not considered to have&#xD;
                  a currently active malignancy if they are in complete remission for &gt; 3 years&#xD;
                  prior to study&#xD;
&#xD;
               -  Uncontrolled severe illness or medical condition (including uncontrolled diabetes&#xD;
                  mellitus)&#xD;
&#xD;
               -  Known HIV infection, active Hepatitis B or C infection&#xD;
&#xD;
               -  Any serious and/or unstable pre-existing psychiatric or other condition that&#xD;
                  could interfere with subject's safety, provision of informed consent, or&#xD;
                  compliance to study procedures&#xD;
&#xD;
               -  Any ongoing toxicity from prior anti-cancer therapy that is &gt; grade 1 and/or that&#xD;
                  is progressing in severity (except alopecia) and delayed hematological recovery&#xD;
                  following last temozolomide cycle&#xD;
&#xD;
               -  Additional anti-cancer treatment for GBM other than study drug and supportive&#xD;
                  measures (i.e. dexamethasone)&#xD;
&#xD;
               -  Inadequate organ and bone marrow function as evidenced by:&#xD;
&#xD;
                    1. Hemoglobin &lt;9.0 g/dL&#xD;
&#xD;
                    2. Absolute neutrophil count &lt;1.5 x 109/L,&#xD;
&#xD;
                    3. Platelet count &lt;100 x 109/L,&#xD;
&#xD;
                    4. AST/SGOT and/or ALT/SGPT &gt;1.5 x ULN;&#xD;
&#xD;
                    5. Total bilirubin &gt;1.0 x ULN,&#xD;
&#xD;
                    6. Serum creatinine &gt;1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine&#xD;
                       clearance will be calculated according to CKD-EPI formula and patients with&#xD;
                       creatinine clearance &lt;60 mL/min should be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hämatologisch onkologische Praxis</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein GmbH</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lars Bullinger, MD</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Lars Bullinger</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

